Cipla share news, announcements and annual reports
NSE: CIPLABSE: 500087Pharmaceuticals & BiotechnologyLarge Cap
Cipla Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1983 on BSE, Feb 1995 on NSE
Last close ₹1,378.90up ₹20.90 (1.54%)BSE ₹1,380.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,358.00.
30 Oct: open ₹1,362.00, high ₹1,381.70, low ₹1,357.00
52-week range of traded prices to 30 Oct 2026
₹1,165.70Low, 2 Apr 2026₹1,593.30High, 30 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,11,397 Cr99th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.45
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.15
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.94%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 14,36,66155.4% delivered
Cipla board meetings
134 filed, newest first. Page 3 of 3.
Aug 2013
1 Aug · Board meeting
Inter alia, to consider Unaudited Financial Results for first quarter ended June 30, 2013.
Jul 2013
15 Jul · Board meeting
May 2013
21 May · Board meeting
Inter-alia to consider the Annual Audited Accounts for the year ended March 31, 2013 and Recommendation of Dividend, if any.
Jan 2013
29 Jan · Board meeting
Inter alia to consider Unaudited Financial Results for third quarter ended December 31, 2012 .
Oct 2012
26 Oct · Board meeting
Inter-alia to consider Unaudited Financial Results for second quarter ended September 30, 2012.
Jul 2012
23 Jul · Board meeting
Inter-alia to consider Unaudited Financial Results for first quarter ended June 30, 2012.
May 2012
30 May · Board meeting
Inter-alia to consider the Annual Audited Accounts for the year ended March 31, 2012 and Recommendation of Dividend, if any.2 May · Board meeting
Inter-alia to consider Unaudited Financial Results for fourth quarter ended March 31, 2012.
Feb 2012
3 Feb · Board meeting
Inter-alia to consider Unaudited Financial Results for third quarter ended December 31, 2011.
Nov 2011
4 Nov · Board meeting
Inter-alia to consider Unaudited Financial Results for second quarter ended September 30, 2011.
Jul 2011
28 Jul · Board meeting
Inter-alia to consider Unaudited Financial Results for first quarter ended June 30, 2011.
Jun 2011
21 Jun · Board meeting
Inter-alia to consider the Annual Audited Accounts for the year ended March 31, 2011 and Recommendation of Dividend, if any.
Apr 2011
27 Apr · Board meeting
Inter-alia to consider Unaudited Financial Results for fourth quarter ended March 31, 2011.
Jan 2011
27 Jan · Board meeting
Inter-alia to consider Unaudited Financial Results for third quarter ended December 31, 2010.
Nov 2010
3 Nov · Board meeting
Inter-alia to consider Unaudited Financial Results for Second quarter ended September 30, 2010.
Aug 2010
23 Aug · Board meeting
Inter-alia to consider special interim dividend for the financial year 2010-2011 to commemorate 75th Anniversary of the Company.5 Aug · Board meeting
Inter-alia to consider Unaudited Financial Results for first quarter ended June 30, 2010.
Jun 2010
15 Jun · Board meeting
Board of Directors at its meeting held on June 15, 2010 have inter-alia approved the following investment in 2 Biotech Companies with a joint venture partner in China: (1) Acquisition of 40% stake in a biotech company based in India through subscription of fresh shares of the company. The biotech company is setting up a state of the art facility for biosimilar products in Goa. Cipla will have rights to market all biosimilar products of the company in India and in international markets; (2) Acquisition of 25% stake in a biotech company in Hong Kong through subscription of fresh shares of the company. The investment will be made by Cipla through a wholly owned overseas subsidiary. The biotech company is setting up a state of the art facility for biosimilar products in Shanghai, China through its wholly owned subsidiary. Cipla will have rights to market biosimilar products of this biotech company in India and in international markets. The total investment for both the aforesaid biotech companies is estimated to be about USD 65 million in a phased manner over a period of 3 years.7 Jun · Board meeting
Inter-alia to consider the Annual Audited Accounts for the year ended March 31, 2010 and Recommendation of Dividend, if any.
Apr 2010
29 Apr · Board meeting
Meeting on 7 May 2010: “Unaudited Financial Results for the qtr ended March 31, 2010”
Jan 2010
20 Jan · Board meeting
Meeting on 28 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009”
Oct 2009
20 Oct · Board meeting
Meeting on 28 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jul 2009
21 Jul · Board meeting
Meeting on 29 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009/Unaudited Financial Results/Raising of funds/Others”7 Jul · Board meeting
Inter-alia to consider the Annual Audited Accounts for the year ended March 31, 2009 and Recommendation of Dividend, if any.
Apr 2009
16 Apr · Board meeting
Meeting on 24 Apr 2009: “Unaudited Financial Results for the qtr ended March 31, 2009”
Jan 2009
14 Jan · Board meeting
Meeting on 22 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
14 Oct · Board meeting
Meeting on 22 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”
Jul 2008
10 Jul · Board meeting
Inter-alia to consider the Annual Accounts for the year ended March 31, 2008, Recommendation of Dividend, if any and Unaudited Financial Results for first quarter ended June 30, 2008.
Apr 2008
17 Apr · Board meeting
Meeting on 25 Apr 2008: “Unaudited Financial Results for the qtr ended March 31, 2008”
Jan 2008
16 Jan · Board meeting
Meeting on 24 Jan 2008: “Unaudited Financial Results for the qtr ended Dec 31, 2007”
Oct 2007
16 Oct · Board meeting
Meeting on 24 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Jul 2007
13 Jul · Board meeting
Inter-alia to consider the Annual Accounts for the year ended March 31, 2007, Recommendation of Dividend, if any and Unaudited Financial Results for the first quarter ended June 30, 2007.
Apr 2007
19 Apr · Board meeting
Meeting on 26 Apr 2007: “Unaudited Financial Results for the Qtr ended March 31, 2007”
Jan 2007
16 Jan · Board meeting
Meeting on 23 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”